Company performance
Add to research
Current Price
as of Jun 20, 2025$2.26
P/E Ratio
N/A
Market Cap
$160.82M
Description
Add to research
Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.
Metrics
Add to research
Overview
- HQSan Diego, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerVTYX
- Price$2.26-4.64%
Trading Information
- Market cap$160.82M
- Float88.62%
- Average Daily Volume (1m)1,971,196
- Average Daily Volume (3m)1,537,951
- EPS-$1.75
Company
- RevenueN/A
- Rev growth (1yr)N/A
- Net income-$27.44M
- Gross marginN/A
- EBITDA marginN/A
- EBITDA-$29.74M
- EV-$136.46M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
- P/B0.69
- Debt/Equity4.55
Documents
Add to research
SEC Filings
Factset Street Account